Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by Dude51on May 09, 2021 12:58pm
311 Views
Post# 33162017

Were moving ahead folks cause Phase 1 human studies is

Were moving ahead folks cause Phase 1 human studies is already paid for:

From  Robert Interview, see more at:

https://claritasinvestors.com/index.php?/topic/855-interview-with-the-boss-bob-farrell-may-3-2021/&tab=comments#comment-2878

"BOB:  CMAX is one of Australia’s largest and most experienced Phase 1 and Phase 2 clinical trial units. The Phase 1 study is expected to begin enrollment in early Q3 this year, and will have a duration of two months. The study will enroll 32 healthy middle-aged volunteers in 4 ascending dose cohorts.  

DREW:  So we have to wait to get funding to pay for this?

BOB:  Not at all.  Funding for the Phase 1 clinical study will be provided from an R&D expense refund that the Company expects to receive from the Australian Taxation Office (the “ATO”) at any time now.  As soon as it arrives, we can proceed.   The ATO provides refunds of up to 43% of qualifying R&D expenditures, and this was a factor in the Company’s decision to conduct much of its research activities in Australia." 

Just remember goofball bashers people can get suied for lying and making public defamitory statements, yes even on Stockhouse keep it up bashers and you will see the inside of a court room.
GLTA

<< Previous
Bullboard Posts
Next >>